A number of firms have modified their ratings and price targets on shares of Global Blood Therapeutics (NASDAQ: GBT) recently:

  • 11/13/2017 – Global Blood Therapeutics was given a new $53.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 11/9/2017 – Global Blood Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $83.00 price target on the stock. They wrote, “GBT reported Q3 earnings last week and provided a brief summary of their progress.””
  • 11/7/2017 – Global Blood Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. “
  • 11/6/2017 – Global Blood Therapeutics had its price target raised by analysts at SunTrust Banks, Inc. to $67.00. They now have a “buy” rating on the stock.
  • 11/1/2017 – Global Blood Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 10/30/2017 – Global Blood Therapeutics was given a new $53.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 10/24/2017 – Global Blood Therapeutics was given a new $51.00 price target on by analysts at Needham & Company LLC. They now have a “buy” rating on the stock.
  • 10/23/2017 – Global Blood Therapeutics had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 10/23/2017 – Global Blood Therapeutics was given a new $53.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 10/18/2017 – Global Blood Therapeutics was given a new $51.00 price target on by analysts at Needham & Company LLC. They now have a “buy” rating on the stock.
  • 10/16/2017 – Global Blood Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. “
  • 10/11/2017 – Global Blood Therapeutics was given a new $53.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 10/10/2017 – Global Blood Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $36.00 price target on the stock. According to Zacks, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. “
  • 10/6/2017 – Global Blood Therapeutics had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $56.00 price target on the stock, up previously from $51.00.
  • 9/27/2017 – Global Blood Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Shares of Global Blood Therapeutics, Inc. (NASDAQ GBT) opened at $38.35 on Friday. Global Blood Therapeutics, Inc. has a 12-month low of $13.35 and a 12-month high of $43.95.

Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same period in the previous year, the company earned ($0.58) earnings per share. equities research analysts predict that Global Blood Therapeutics, Inc. will post -2.53 EPS for the current year.

In other news, VP Peter Radovich sold 12,500 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $35.00, for a total value of $437,500.00. Following the completion of the sale, the vice president now directly owns 2,684 shares of the company’s stock, valued at $93,940. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jung Choi sold 3,000 shares of the stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now directly owns 141,655 shares of the company’s stock, valued at $4,249,650. The disclosure for this sale can be found here. Insiders have sold 91,500 shares of company stock valued at $3,093,350 in the last ninety days. Company insiders own 5.30% of the company’s stock.

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Receive News & Ratings for Global Blood Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.